stockrow
Saturday 7 November 2026
Export SLDB’s income statement to Excel — free account
Solid Biosciences Inc.
SLDB Healthcare Biotechnology
Solid Biosciences Inc.’s revenue for fiscal 2022 (year ended December 2022) was $8.1 million.
- EPS
- +25.6%
- Free cash flow
- −39.6%
Quarter to September 2026, against a year earlier
6.57
0.39
+6.31%
Follow SLDB
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(109.90%) | (57.37%) | (65.50%) | (76.87%) | |
| (82.78%) | (50.02%) | (56.83%) | (64.86%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(98.96%) | (51.77%) | (55.90%) | (63.60%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(1.80) | (1.57) | (1.31) | (1.33) | |
Free Cash Flow |
(157.36) | (172.78) | (187.72) | (200.21) | |
Capital Expenditures |
(1.07) | (1.11) | (0.88) | (1.29) | |
| Other line items | |||||
Cash ROIC |
(42.63%) | (22.87%) | (24.95%) | (28.95%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
882.79 | — | — | — | |
Operating CF/Net income |
0.90 | 0.90 | 0.90 | 0.92 | |
Depreciation/Fixed assets |
(0.06) | (0.14) | (0.36) | (0.67) | |
Capex/Depreciation |
4.49 | 1.99 | 0.62 | 0.51 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.79) | (1.56) | (1.30) | (1.32) | |
Capex per Share |
(0.01) | (0.01) | (0.01) | (0.01) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 6 Nov 2026